

## Exercise of warrants a great success

Dijon, 13 December 2019

**CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing a portfolio of innovative combined drugs for use in emergency situations,** today announces the results of the exercise of equity warrants issued and allocated free of charge to all existing shareholders on 18 July 2019, in the proportion of 1 warrant for each share held, with 9 warrants allowing holders to subscribe for 1 share at the price of €1.80.

At the end of the exercise period of the warrants, which expired after trading on 10 December 2019, 15,779,196 warrants had been exercised out of 18,447,028 warrants issued – **an exercise rate of 85.54%** – meaning a total of 1,753,244 new Crossject shares issued for €3,155,839.20. The new shares immediately bear dividend rights and have been listed on the same line as the existing shares. Warrants not exercised after trading on 10 December 2019 have lapsed.

As stated in the press release of 19 November 2019, Crossject's funding requirement for the next 12 months is €12 million. The proceeds from the exercise of the warrants, i.e. €3.2 million, combined with IdVectoR funding (€2.6 million), plus repayable aid and advances, the research tax credit and the revenue resulting from the signing of commercial agreements may be supplemented by other funding as necessary.

Patrick Alexandre, Chairman of the Management Board of Crossject, said: *"On behalf of all Crossject teams, I would like to thank our shareholders, who participated massively in the transaction, thereby showing us their support. Since the beginning of the year, Crossject has made significant announcements, with the signing of a cooperation agreement with the United States Department of Defense, the signing of a commercial agreement in Germany and the receipt of pharmaceutical establishment status. This cash injection will allow us to continue our development and notably the constitution of the dossiers for our first AMM<sup>1</sup> filings."*

---

<sup>1</sup> MA: Marketing authorisation



## Contacts:

### Crossject

Patrick Alexandre

[info@crossject.com](mailto:info@crossject.com)

### Investor relations

#### CIC Market Solutions

Catherine Couanau +33 (0)1 53 48 81 97

[catherine.couanau@cic.fr](mailto:catherine.couanau@cic.fr)

### Press relations

#### Buzz & Compagnie

Mélanie Voisard +33 (0)3 80 43 54 89

[melanie.voisard@buzzetcompagnie.com](mailto:melanie.voisard@buzzetcompagnie.com)

Christelle Distinguin +33 (0)3 80 43 54 89

[christelle.distinguin@buzzetcompagnie.com](mailto:christelle.distinguin@buzzetcompagnie.com)

## About CROSSJECT • [www.crossject.com](http://www.crossject.com)

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.

Translation for information purposes only. In case of discrepancy between the French and English versions of this press release, only the French version should be deemed valid